Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.
“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.
An interview with Alan Stitt about research in the AMD field.
Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.
Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.
Diabetic eye diseases affect millions of people globally, and still there's a high unmet need in diagnosis and treatment. It's high time to get the message across to risk groups.
In this post, we’ll share some striking facts and numbers about diabetes and diabetic eye disease.
Diabetic eye disease is currently one of the leading causes of preventable blindness in the working population worldwide. Early treatment and diagnosis is crucial for prevention.
This November, in support of Diabetic Eye Disease Awareness Month, Oxurion is partnering with Prevent Blindness and its sight saving efforts.
PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains professor Alan Stitt.
Vinciane Vangeersdaele joined the Oxurion leadership team this past year. With extensive experience in commercializing pharmaceutical portfolios worldwide, including in ...